1650 related articles for article (PubMed ID: 27913228)
21. Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma.
Chan AWH; Tong JHM; Kwan JSH; Chow C; Chung LY; Chau SL; Lung RWM; Ng CSH; Wan IYP; Mok TSK; To KF
Mod Pathol; 2018 Sep; 31(9):1381-1390. PubMed ID: 29713040
[TBL] [Abstract][Full Text] [Related]
22. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
[TBL] [Abstract][Full Text] [Related]
23. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
Fujimoto D; Yamashita D; Fukuoka J; Kitamura Y; Hosoya K; Kawachi H; Sato Y; Nagata K; Nakagawa A; Tachikawa R; Date N; Sakanoue I; Hamakawa H; Takahashi Y; Tomii K
Anticancer Res; 2018 Dec; 38(12):6891-6895. PubMed ID: 30504406
[TBL] [Abstract][Full Text] [Related]
24. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
[TBL] [Abstract][Full Text] [Related]
25. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
26. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.
Maule JG; Clinton LK; Graf RP; Xiao J; Oxnard GR; Ross JS; Huang RSP
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302564
[TBL] [Abstract][Full Text] [Related]
27. Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study.
Tsimafeyeu I; Imyanitov E; Zavalishina L; Raskin G; Povilaitite P; Savelov N; Kharitonova E; Rumyantsev A; Pugach I; Andreeva Y; Petrov A; Frank G; Tjulandin S
Sci Rep; 2020 Mar; 10(1):3928. PubMed ID: 32127616
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
Munari E; Rossi G; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Netto GJ; Hoque MO; Brunelli M; Martignoni G; Haffner MC; Moretta F; Pegoraro MC; Cavazza A; Samogin G; Furlan V; Mariotti FR; Vacca P; Moretta L; Bogina G
Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568
[TBL] [Abstract][Full Text] [Related]
29. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY
Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
[TBL] [Abstract][Full Text] [Related]
30. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
Savic S; Berezowska S; Eppenberger-Castori S; Cathomas G; Diebold J; Fleischmann A; Jochum W; Komminoth P; McKee T; Letovanec I; Jasarevic Z; Rössle M; Singer G; von Gunten M; Zettl A; Zweifel R; Soltermann A; Bubendorf L
Virchows Arch; 2019 Jul; 475(1):67-76. PubMed ID: 31127385
[TBL] [Abstract][Full Text] [Related]
32. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.
Scheel AH; Baenfer G; Baretton G; Dietel M; Diezko R; Henkel T; Heukamp LC; Jasani B; Jöhrens K; Kirchner T; Lasitschka F; Petersen I; Reu S; Schildhaus HU; Schirmacher P; Schwamborn K; Sommer U; Stoss O; Tiemann M; Warth A; Weichert W; Wolf J; Büttner R; Rüschoff J
Histopathology; 2018 Feb; 72(3):449-459. PubMed ID: 28851100
[TBL] [Abstract][Full Text] [Related]
33. External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different.
Dodson A; Parry S; Lissenberg-Witte B; Haragan A; Allen D; O'Grady A; McClean E; Hughes J; Miller K; Thunnissen E
J Pathol Clin Res; 2020 Apr; 6(2):138-145. PubMed ID: 31849189
[TBL] [Abstract][Full Text] [Related]
34. Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC.
Sughayer MA; Alnaimy F; Alsughayer AM; Qamhia N
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):663-666. PubMed ID: 30024424
[TBL] [Abstract][Full Text] [Related]
35. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC
Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709
[TBL] [Abstract][Full Text] [Related]
36. [Consistency of PD-L1 immunohistochemical detection platforms in biopsy samples with advanced lung adenocarcinoma: a multicenter study].
Yuan P; Guo CY; Li Y; Jiang LL; Liu YP; Liu XY; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):840-844. PubMed ID: 30423607
[No Abstract] [Full Text] [Related]
37. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
38. Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma.
Nambirajan A; Husain N; Shukla S; Kumar S; Jain D
Indian J Med Res; 2019 Oct; 150(4):376-384. PubMed ID: 31823919
[TBL] [Abstract][Full Text] [Related]
39. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
40. Comparison of
Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
